{
    "clinical_study": {
        "@rank": "136352", 
        "arm_group": [
            {
                "arm_group_label": "PF-04457845", 
                "arm_group_type": "Active Comparator", 
                "description": "PF-04457845 will be administered orally at 4mg daily for four weeks."
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo (sugar pill) will be administered orally at 4mg daily for four weeks."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this trial is to examine the safety, tolerability and feasibility in the use\n      of a FAAH inhibitor for the treatment of adults with Tourette syndrome."
        }, 
        "brief_title": "FAAH Inhibitor Trial for Adults With Tourette Syndrome", 
        "condition": "Tourette Syndrome", 
        "condition_browse": {
            "mesh_term": "Tourette Syndrome"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adult between 18-60 years of age\n\n          -  Meet DSM IV criteria for the diagnosis of Tourette's syndrome\n\n          -  Significant current tic symptoms: YGTSS total tic score greater than or equal to 22\n             at baseline\n\n          -  On stable psychiatric medication regimen for a minimum of 4 weeks prior to beginning\n             the trial.\n\n          -  Accepted method of birth control\n\n        Exclusion Criteria:\n\n          -  Comorbid bipolar disorder, psychotic disorder, substance use disorder, developmental\n             disorder or intellectual disability (IQ<70).\n\n          -  Current use of medications that have significant effects on the cannabinoid or\n             dopamine systems. Subjects will be specifically excluded for recent use (within last\n             8 weeks) of antipsychotic medications, dopamine agonists or psychostimulants.\n\n          -  Recent change (less than 4 weeks) in other medications that have potential effects on\n             tic severity (such as alpha-2 agonists (guanfacine, clonidine or prazosin), SSRIs,\n             clomipramine, naltrexone, lithium, anxiolytics, topiramate, baclofen etc.).\n             Medication change is defined to include dose changes or medication discontinuation.\n\n          -  Recent change in behavioral treatment for Tourette syndrome or comorbid conditions\n             (i.e. OCD) within the last 4 weeks or initiation of behavioral therapy for tics\n             within the last 12 weeks.\n\n          -  Positive pregnancy test or drug screening test\n\n          -  History of cannabis dependence\n\n          -  Significant Medical Comorbidity"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "60 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "10", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 6, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02134080", 
            "org_study_id": "1403013669"
        }, 
        "intervention": [
            {
                "arm_group_label": "PF-04457845", 
                "description": "PF-04457845 will be administered orally at 4mg daily for four weeks.", 
                "intervention_name": "PF-04457845", 
                "intervention_type": "Drug", 
                "other_name": "fatty acid amide hydrolase (FAAH) inhibitor"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Placebo will be administered orally at 4mg daily for four weeks.", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug", 
                "other_name": "Sugar Pill"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Tourette Syndrome", 
            "FAAH-Inhibitor", 
            "Tics", 
            "Tic Disorders"
        ], 
        "lastchanged_date": "May 6, 2014", 
        "location": {
            "contact": {
                "email": "jilian.mulqueen@yale.edu", 
                "last_name": "Jilian M. Mulqueen, BA", 
                "phone": "203-737-4809"
            }, 
            "facility": {
                "address": {
                    "city": "New Haven", 
                    "country": "United States", 
                    "state": "Connecticut", 
                    "zip": "06519"
                }, 
                "name": "Connecticut Mental Health Center"
            }, 
            "investigator": {
                "last_name": "Michael H. Bloch, MD, MS", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "FAAH Inhibitor Trial for Adults With Tourette Syndrome", 
        "overall_contact": {
            "email": "jilian.mulqueen@yale.edu", 
            "last_name": "Jilian M. Mulqueen, BA", 
            "phone": "203-737-4809"
        }, 
        "overall_official": {
            "affiliation": "Yale University", 
            "last_name": "Michael H. Bloch, MD, MS", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "May 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Yale Global Tic Severity Scale (Total Tic Score)", 
            "measure": "Improvement in Tic Severity", 
            "safety_issue": "No", 
            "time_frame": "Evaluated each time subject seen over approximately 12 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02134080"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Premonitory Urge for Tics Scale (PUTS)", 
                "measure": "Improvement of Premonitory Urges", 
                "safety_issue": "No", 
                "time_frame": "Evaluated each time subject seen over approximately 12 Weeks"
            }, 
            {
                "description": "Yale-Brown Obsessive-Compulsive Scale (Y-BOCS)", 
                "measure": "Improvement in Obsessive Compulsive Disorder (OCD) Severity", 
                "safety_issue": "No", 
                "time_frame": "Evaluated every two weeks over the course of approximately 12 weeks"
            }, 
            {
                "description": "Tourette Syndrome Symptom List (TSSL)", 
                "measure": "Self-Report of Tic Severity", 
                "safety_issue": "No", 
                "time_frame": "Evaluated each time subject seen over approximately 12 weeks"
            }, 
            {
                "description": "Modified Rush Video Rating Scale", 
                "measure": "Video-Tape Ratings of Tic Severity", 
                "safety_issue": "No", 
                "time_frame": "Evaluated every two weeks over the course of approximately 12 weeks"
            }, 
            {
                "description": "Connors Adult Attention Deficit Hyperactivity Rating Scale", 
                "measure": "ADHD Severity", 
                "safety_issue": "No", 
                "time_frame": "Evaluated every two weeks over the course of approximately 12 weeks"
            }, 
            {
                "description": "Hamilton Rating Scale for Depression", 
                "measure": "Depression Severity", 
                "safety_issue": "No", 
                "time_frame": "Evaluated every two weeks over the course of approximately 12 weeks"
            }, 
            {
                "description": "Hamilton Rating Scale for Anxiety", 
                "measure": "Anxiety Severity", 
                "safety_issue": "No", 
                "time_frame": "Evaluated every two weeks over the course of approximately 12 weeks"
            }, 
            {
                "description": "Clinical Global Improvement Scale", 
                "measure": "Overall improvement", 
                "safety_issue": "No", 
                "time_frame": "Evaluated each time subject seen over approximately 12 Weeks"
            }, 
            {
                "description": "Adverse Events Rating Scale", 
                "measure": "Number of Adverse Events", 
                "safety_issue": "Yes", 
                "time_frame": "Evaluated each time subject seen over approximately 12 Weeks"
            }
        ], 
        "source": "Yale University", 
        "sponsors": {
            "collaborator": {
                "agency": "Tourette Syndrome Association", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Yale University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}